Safety of CDKI combined with radiotherapy in hormone receptor positive breast cancer

被引：0
|
作者：
Falivene, S. [1 ]
Scipilliti, E. [2 ]
Ferraioli, P. [2 ]
Ravo, V. [2 ]
Muto, P. [2 ]
机构：
[1] INT IRCCS Fdn Pascale, Rdiotherapy, Naples, Italy
[2] INT IRCCS Fdn Pascale, Radiotherapy, Naples, Italy
来源：
RADIOTHERAPY AND ONCOLOGY | 2023年 / 182卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO-1247
引用
收藏
页码：S998 / S998
页数：1
相关论文
共 50 条
  • [1] Hormone receptor positive breast cancer
    Ma, Cynthia
    CANCER RESEARCH, 2023, 83 (05)
  • [2] SAFETY OF COMBINED EXEMESTANE AND EVEROLIMUS IN POSTMENOPAUSAL HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER PATIENTS - A RETROSPECTIVE ANALYSIS
    Gilchrist, Jenny
    Todd, J.
    Kefford, R.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 176 - 176
  • [3] Safety and ef ficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor -positive breast cancer and the of biomarkers
    Yi, Zongbi
    Liu, Binliang
    Sun, Xiaoying
    Rong, Guohua
    Wang, Wenna
    Li, Hui
    Guan, Xiuwen
    Li, Lixi
    Zhai, Jingtong
    Li, Chunxiao
    Qian, Haili
    Ma, Fei
    Xu, Binghe
    BREAST, 2020, 52 : 17 - 22
  • [4] The Immunology of Hormone Receptor Positive Breast Cancer
    Goldberg, Jonathan
    Pastorello, Ricardo G.
    Vallius, Tuulia
    Davis, Janae
    Cui, Yvonne Xiaoyong
    Agudo, Judith
    Waks, Adrienne G.
    Keenan, Tanya
    McAllister, Sandra S.
    Tolaney, Sara M.
    Mittendorf, Elizabeth A.
    Guerriero, Jennifer L.
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [5] Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer
    Sehdev, S.
    Martin, G.
    Sideris, L.
    Lam, W.
    Brisson, S.
    CURRENT ONCOLOGY, 2009, 16 : S16 - S25
  • [6] Androgen Receptor in Hormone Receptor-Positive Breast Cancer
    Khan, Ashfia Fatima
    Karami, Samaneh
    Peidl, Anthony S.
    Waiters, Kacie D.
    Babajide, Mariam Funmi
    Bawa-Khalfe, Tasneem
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (01)
  • [7] Liver toxicities during cyclin-dependent kinase inhibitors (CDKi) in patients affected by hormone receptor-positive breast cancer (BC)
    Paratore, C.
    Audisio, M.
    Bombaci, S.
    Bungaro, M.
    Dionisio, R.
    Ferrari, G.
    Gaudino, E.
    Grassi, L.
    Hotca, A.
    Loddo, C.
    Manuguerra, G.
    Manzin, E.
    Novello, S.
    Numico, G.
    Persano, I.
    Sculli, C.
    Sperone, P.
    Valsecchi, A. A.
    Zucchini, G.
    Vellani, G.
    ANNALS OF ONCOLOGY, 2023, 34 : S379 - S379
  • [8] Cyclin-dependent kinase 4/6 inhibitors (CDKI)-associated venous thromboembolism in patients with hormone receptor (HR)-positive breast cancer
    Thein, K. Z.
    Htut, T. Win
    Myat, Y. M.
    Han, M. M.
    Oo, T. H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1284 - S1284
  • [9] Disparities in Hormone Receptor-Positive Breast Cancer
    Esther R. Ogayo
    Elizabeth A. Mittendorf
    Olga Kantor
    Current Breast Cancer Reports, 2024, 16 : 106 - 115
  • [10] Disparities in Hormone Receptor-Positive Breast Cancer
    Ogayo, Esther R.
    Mittendorf, Elizabeth A.
    Kantor, Olga
    CURRENT BREAST CANCER REPORTS, 2024, 16 (01) : 106 - 115
12345